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Abstract  
Growth hormone (GH) deficiency and acromegaly serve as good models for investigating the 
effects of GH on bone remodelling. However, the results from various studies are rather 
conflicting. The aim of our study was to estimate the potential role of gender, disease activity 
and duration on both calcaneus quantitative ultrasound (QUS) parameters and bone turnover 
markers in patients with acromegaly. Thirty-six acromegalic patients (17 men, 19 women) 
and three age and gender adjusted controls for every patient were included in the study. The 
disease was active in 22 patients, and was considered cured in 14 of them. In each subject, 
quantitative ultrasound of the heel and parameters of bone turnover (bone alkaline 
phosphatase, β-crosslaps, and osteocalcin) were measured. The results demonstrated lower 
QUS values in acromegalic patients compared with the controls. When stratified by gender, 
the differences in QUS parameters were significant in men, but not in women. Male patients 
with active disease had significantly lower QUS values than those in remission. Such 
differences were not observed among women. Multiple regression model indicated strong 
association between disease activity and the QUS parameters. The group of patients with 
active disease had a higher level of serum β-crosslaps, while osteocalcin concentration was 
significantly increased only in male patients with active disease. The results of our study 
suggest significantly lower QUS values and increased bone turnover in male patients with 
active acromegaly. The disease activity is the strongest predictor of the QUS parameters in 
acromeglic patients. 
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Introduction  
Growth hormone (GH) and insulin-like growth factors (IGFs) are important regulators 
of bone remodelling process. Both GH and IGF-1 influence osteoblast differentiation and 
proliferation (1, 2). Two distinctive clinical conditions, GH deficiency (GHD) and 
acromegaly, serve as good models for investigating the effects of GH on bone metabolism. 
Several studies revealed that patients with GHD have reduced bone mass and increased 
fracture risk (3-5).  
Although it is generally thought that chronic GH excess in acromegalic patients 
influences bone metabolism, the results from various studies are rather conflicting. It seems 
that other hormones, namely sex steroids as the most important ones, modulate the net 
GH/IGF-1 effect on bone (6, 7). Some studies reported no differences in bone mineral density 
(BMD) at spine and femur between acromegalic patients and controls (8, 9), while others 
reported lower (10) or even higher (11) values. The major limitations of these studies were a 
small size of the sample or a lack of analysis regarding gender or disease activity. Although 
acromegaly has often been associated with osteoporosis (12), no study revealed increased 
fracture rate in acromegalic patients. Moreover, a recent study showed decreased fracture risk 
in acromegaly (13). Several studies reported the anabolic effect of GH/IGF-1 axis on cortical 
bone, with either no effect or negative effect on the trabecular bone BMD (7, 12, 14). All the 
studies were based on measurements of bone density by dual energy x-ray absorptiometry 
(DXA). However, as DXA provides no information on bone microarhitecture, the individual 
risk of fracture cannot be explained solely by BMD measured by DXA. This observation 
suggests that fracture risk prediction could be improved by the evaluation of other bone 
characteristics such as trabecular microstructure.  
Quantitative ultrasound (QUS) has been extensively used in the last decade, due to 
some important advantages over DXA: it is inexpensive, ionisation-free and portable. The 
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speed of low-frequency ultrasound through bone depends on bone quality and density. QUS 
reveals physical properties of the bone determined by bone composition and structure. Thus, it 
provides useful information not only on bone mass, but also on bone tissue architecture and 
elasticity. Several studies confirmed the QUS as a good diagnostic tool for detecting 
individuals at risk of fragility fracture (15-18). However, to our knowledge, only one study 
reported the influence of GH excess on calcaneus QUS parameters (19). In this regard, the 
aim of the present study was to estimate the potential role of gender, disease activity and 
duration on calcaneus QUS values and bone markers concentration in patients with 
acromegaly.  
 
Materials and methods  
Subjects 
Thirty-six patients (17 men, aged 48.5±10.6 and 19 women, aged 52.5±10.8) with 
acromegaly referred to the Department of Endocrinology, University Hospital of Zagreb, in 
the period between July 2003 and October 2005 were included in the study. Two female 
patients were excluded from the study as they had been treated with agents affecting bone 
metabolism (one alendronate, one high dose corticosteroids). Three age and gender adjusted 
controls for every patient were obtained from a dataset used to create the Croatian general 
population ultrasound measurements standards (20). Each patient signed an informed consent 
before entering the study. The Local Ethics Committee approved the study.  
The diagnosis of acromegaly was based on characteristic clinical features, failure to 
suppress serum GH level below 1 µg/l after oral glucose tolerance test and high serum IGF-1 
level. Acromegaly cure was defined by normal IGF-1 level for age, and suppression of GH 
level below 1ug/l after glucose load. The disease was active in 22 patients (10 recently 
diagnosed, 12 previously unsuccessfully treated by surgery or radiotherapy) and 14 had been 
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considered cured. Among female patients, 11 had an active disease, and 8 were considered 
cured, while among male patients, 11 had an active disease and 6 were considered cured. The 
average duration of remission was 82.0±15.02 months. 
 Females with regular menstrual cycles were considered as having normal gonadal 
function. Similarly, normal testosterone concentration and the absence of clinical symptoms 
of hypogonadism were considered proof of normal gonadal function in males. Ten female 
patients (7 with active disease (63%) and 3 cured (38%)) were postmenopausal. One cured 
female patient was postoperatively given estrogen replacement.  Six male patients (4 with 
active disease (36%) and 2 cured (33%)) were hypogonadal. Four male patients (1 with active 
disease, 3 cured) were postoperatively given testosterone. Seven male (4 with active disease, 
3 cured) and 8 female patients (5 with active disease, 3 cured) were given replacement of 
other hormones (levothyroxine, hydrocortisone, or both). 
Height and weight were measured without shoes using a portable stadiometer and a 
digital scale.  
Serum IGF-1 was measured by enzyme-linked immunosorbent assay (ELISA; 
Biocode-Hycel, Belgium) and GH level was assayed by radioimmunoassay (RIA; IBL 
Germany). Bone alkaline phosphatase, osteocalcin and β-crosslaps levels were measured by 
ELISA (Nordic Bioscience Diagnostics) and the level of free testosterone was measured by 
RIA (DPC). 
 
 
Quantitative ultrasound 
In each subject, a broadband ultrasound attenuation (BUA) and speed of sound (SOS) 
of the heel were measured using the Sahara ultrasound (Hologic). The left foot was examined 
if there was no history of fracture or other relevant foot disease (in such cases the right foot 
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was measured). Before the first measurement on the respective day, quality assurance was 
performed using the calibrating phantom. The quantitative ultrasound index (QUI) was 
calculated by the device software. Coefficients of variations were 6.5% for BUA, 0.2 % for 
SOS and 2.8% for QUI. 
 
Statistical analysis 
The ultrasound measurements were expressed as the mean and standard deviation. We 
used an independent sample t-test to compare ultrasound measurements between patients with 
acromegaly and controls, and between patients with active disease and those in remission. 
Correlations were assessed using Pearson’s test. The effect of disease activity on QUS 
parameters was assessed in the multiple regression model, which was adjusted for gender, 
body mass index and gonadal status effects. The analysis was performed in the SPSS 
statistical package, version 12.0.0 (SPSS Inc, Chicago, IL, USA), with statistical significance 
set at P<0.05.  
 
 
Results 
The final sample consisted of 17 male patients and 19 female patients, with 51 male 
and 57 female controls. The initial analysis revealed higher ultrasound values among controls, 
with the difference being more pronounced among males (Table 1). The statistical analysis 
revealed significant differences between the patients and controls in males, and no differences 
in females, except for the borderline in significant finding in the case of BUA (Table 1). 
Further analysis among patients with acromegaly revealed significant differences in 
ultrasound measurements among male patients in the active disease stage and in remission, 
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and the absence of such a difference among females (Table 2). Multiple regression model 
indicated strong association between disease activity and the QUS parameters (Table 3).  
QUS values in patients with the cured disease did not significantly differ from those 
observed in the control groups.  
In both males and females, patients with active disease had a higher serum level of β-
crosslaps while the osteocalcin concentration was significantly increased only in males (Table 
2). 
We did not find a significant correlation between the IGF-1 and GH with the QUI (r=-
0.11, P=0.622; r=0.19, P =0.445, respectively) among the patients in the active disease stage. 
Similarly, no significant correlation was found between the QUI and disease duration (disease 
duration-QUI r=-0.25, P =0.270).  
 
 
Discussion 
The present study supports the important role of chronic GH excess on bone 
properties, and its dependence on gender and disease activity. A study that previously 
analysed calcaneus QUS parameters in acromegalic patients (19) used a different QUS device 
(Achilles, Lunar). The main advantage of the current study was the representativeness of the 
control group, obtained from the database used to create normative data for QUS 
measurements in the general population of Croatia. The results demonstrated decreased QUS 
measurements in acromegalic patients compared to control subjects, suggesting impaired bone 
quality. In a similar manner, lower SOS, BUA and QUI values were observed in patients with 
active disease in comparison with the cured ones. Moreover, QUS results in the cured patients 
did not significantly differ from those in healthy subjects matched for age and sex, which 
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suggests that the QUS parameters changes are completely reversible after acromegaly has 
been cured. 
Increased bone turnover has previously been documented in patients with acromegaly 
(21, 22, 23). Moreover, growth hormone treatment in elderly osteoporotic women has been 
shown to increase both bone resorption and bone formation markers (24). In accordance with 
those reports, this study revealed higher β-crosslaps and osteocalcin levels in subjects with 
active disease.  
However, differences in the QUS measurements between patients and controls were 
significant in males while the same outcome was not observed in females, which means that 
the disease affects men more severely than women. In the multiple regression model the 
association between gender and QUS parameters was significant in the case of QUI, and 
borderline significant for the BUA and SOS, which speaks in favour of the above hypothesis. 
A similar finding was reported by Bolanowski et al. (19). Based on these data it seems that the 
effect of the GH/IGF-1 axis on bone metabolism is stronger in men than in women, but the 
reason for the observed gender discrepancy is not quite clear. It is known that the GH/IGF-1 
axis is involved in the pathogenesis of hyperandrogenism in polycystic ovarian syndrome 
(25). In a similar manner, the gender discrepancy in bone metabolism between male and 
female acromegalic patients could be attributed to the androgenic effect of GH/IGF-1 excess 
on bone (26). Tütüncü et al. hypothesized that this androgenic effect is more important in 
females, than in males, who already have maximal androgen influence on bone (27). Another 
possible explanation can be that in female patients, in contrast to males, the impact of 
estrogen on bone metabolism could possibly overcome the GH/IGF-1 effect. However, in the 
present study the female patient group was more heterogeneous than the male group, with 10 
out of 19 patients being postmenopausal at the time of the observation. This also has to be 
considered when looking into gender discrepancy in the QUS parameters and bone markers.   
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When dealing with the results of the present study we should not discard the 
possibility that the local conditions of the bone and surrounding heel tissue may introduce 
bias, as well as possible different calcaneal architecture between male and female patients 
with acromegaly. Changes of joint morphology may be associated with the GH excess. 
Osteoarthritis and secondary degenerative changes were described as a common feature in 
acromegaly (28, 29). A recent study reported increased thickness of articular cartilages of 
shoulder, wrist and knees, as well as the heel tendon size, in patients with acromegaly (30). 
Moreover, hypertrophy of periarticular soft tissue was also found in those patients (31). All 
the mentioned changes could influence the calcaneal QUS measurements. Moreover, lower 
BUA and SOS values could be the result of soft tissue swelling (32). However, no ankle 
oedema was observed in the patients included in the study.  
The absence of the correlation between the IGF-1 and GH levels with the QUI is not in 
line with the previous study reporting an inverse correlation of the QUS indices with GH, but 
not with IGF-1 (19). Studies that evaluated the effects of acromegaly on bone density 
measured by DXA observed a significant correlation of IGF-1 with femoral neck BMD 
mainly containing cortical bone, but not with lumbar spine BMD which is prevalently 
composed of trabecular bone (7, 14). 
Other factors, such as the duration and activity of the disease could also influence the 
bone metabolism in acromegalic patients. We did not find significant correlation between the 
disease duration and the QUS parameters. However, the estimation of the duration of the 
disease was based on the patients’ recall. The unreliable accuracy of the data collected in such 
a way could compromise the validity of the results.  
The shortcomings of this study primarily include the small size of the sample. 
Nevertheless, most of the previously published studies were also based on small sample sizes. 
A possible solution to this issue could be the development of a joined dataset, which would 
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enable a cross-comparison and meta-analysis of the available data. In such a manner, more 
reliable results of the acromegalic effects on the bone properties could be obtained.  
In conclusion, besides bone density, calcaneus ultrasound can provide additional 
information on bone properties in acromegalic patients. Our data indicated lower levels of 
BUA, SOS and QUI in patients with acromegaly compared to healthy controls, suggesting 
impaired bone quality. Similarly, decreased QUS values and increased bone turnover markers 
were observed in patients with active acromegaly in comparison with the cured ones. The 
differences were more pronounced in males probably due to the androgenic effect of GH/IGF-
1, which seems to be more important in females than in males. Multiple regression model 
indicated strong association between disease activity and the QUS parameters. 
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TABLES: 
Table 1. Calcaneus quantitative ultrasound parameters in male and female patients with 
acromegaly and in controls  
Table 2.  Calcaneus quantitative ultrasound parameters and markers of bone turnover in male 
and female acromegalic patients with active and controlled disease  
Table 3. Multiple regression model of the QUS parameters 
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Table 1.    
 Males Females 
Variable 
Patients 
(n=17) 
Controls 
(n=51) 
P 
Patients 
(n=19) 
Controls 
(n=57) 
P 
Age (y) 48.5±10.6 48.3±10.2 NS 52.5±10.8 51.9±10.3 NS 
BMI (kg/m2) 29.9±4.8 27.3±3.8 <0.05 28.6±5.9 27.7±5.7 NS 
QUI 77.2±23.7 100.7±21.8 <0.001 84.5±15.4 90.8±17.9 NS 
SOS 1526.8±33.0 1555.3±34.9 <0.05 1534.0±27.9 1539.9±28.3 NS 
BUA 56.9±29.1 83.1±20.3 <0.05 64.8±12.4 72.6±16.2 0.06 
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Table 2.  
 Males  Females  
Variable 
Active disease 
(n=11) 
Cured 
(n=6) 
P 
Active disease 
(n=11) 
Cured 
(n=8) 
P 
Age (y) 49.5±13.2 47.3±3.1 NS 49.4±7.8 55.2±13.8 NS 
BMI (kg/m2) 29.2±3.3 31.2±7.0 NS 29.1±3.6 27.9±8.3 NS 
Basal GH 31.8±44.9 0.5±0.3 <0.001 25.7±54.5 1.6±1.8 <0.001 
IGF-1 116.7±47.8 34.7±14.7 <0.001 110±41.7 47.2±21.9 <0.001 
BAP 9.8±5.9 8.0±1.2 NS 13.8±11.8 12.5±8.6 NS 
Osteocalcin 16.1±4.9 9.7±3.0 <0.05 25.8±18.5 18.3±17.8 NS 
β-Crosslaps 0.5±0.2 0.3±0.2 <0.05 0.8±0.4 0.4±0.4 <0.05 
QUI 66.7±17.2 96.3±22.7 <0.05 79.3±9.1 88.2±18.2 NS 
SOS 1510.1±21.4 1557.2±29.0 <0.05 1523.6±16.6 1540.2±32.5 NS 
BUA 45.3±24.0 78.2±26.5 <0.05 62.6±9.5 66.4±14.4 NS 
 
 
 14 
Table 3.  
 P (QUI) P (BUA) P (SOS) 
Hypogonadism 0.436 0.235 0.441 
Active disease 0.020 0.007 0.014 
Gender 0.012 0.051 0.060 
Body mass index 0.071 0.111 0.123 
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